Genmab

1.377 DKK

+0,33 %

GMAB

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Mindre end 1K følgere

Sammenligne

+0,33%

-14,34%

-7,74%

-14,42%

-23,71%

-28,09%

-38%

-17,05%

+3.938,12%

Genmab er et farmaceutisk selskab. Virksomheden har specialiseret sig i forskning og udvikling af antistoffer, som hovedsageligt bruges til behandling af kræftpatienter med lymfatisk leukæmi og solide tumorer. Forskning og udvikling er baseret på virksomhedens egen udviklede tekniske platform, og driften foregår på globalt plan. Genmab blev grundlagt i 1999 og har sit hovedkontor med beliggenhed i København.

Læs mere

Markedsværdi

91,14 mia. DKK

Aktieomsætning

19,14 mio. DKK

Omsætning

16,47 mia.

EBIT %

32,3 %

P/E

20,66

Udbytteafkast, %

Finanskalender

12.2

2025

Årsrapport '24

12.3

2025

Generalforsamling '25

8.5

2025

Delårsrapport Q1'25

ViserAlle indholdstyper

Selskabsmeddelelse23.1.2025, 20.08

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab

Selskabsmeddelelse22.1.2025, 11.23

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab

Pressemeddelelse3.1.2025, 18.55

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Genmab

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Aktier i Vælten - Et tilbageblik på bevægelserne i OMXC25 i 2024, og nogle forudsigelser for 2025

Video3.1.2025, 16.28 af

Michael Friis, Rasmus Køjborg

Aktier i Vælten - Et tilbageblik på bevægelserne i OMXC25 i 2024, og nogle forudsigelser for 2025

I denne uges Aktier i Vælten runder vi 2024 af med at se nærmere på hvordan OMXC25, og nogle af de underliggende aktier i indekset har klaret sig i det forgangne år. Samtidig kigger vi ind i hvordan nogle af de indekstunge aktier måske kan udvikle sig i 2025.

Pressemeddelelse11.12.2024, 13.20

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Genmab

Pressemeddelelse9.12.2024, 17.00

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab

Pressemeddelelse8.12.2024, 16.00

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Genmab

Pressemeddelelse8.12.2024, 00.12

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Genmab

Selskabsmeddelelse3.12.2024, 21.35

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab

Selskabsmeddelelse3.12.2024, 12.07

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Genmab

Video28.11.2024, 13.43

Aktier i Vælten - Genmab, NKT og Carlsberg: Er de på tilbud her i Black Week?

Med 'Black Week' over os har vi i denne uges Aktier i Vælten set nærmere på C25 aktier, der baseret på EV/EBIT (NTM) handles tæt på deres laveste niveau de seneste 10 år. Ud fra data trukket fra Capital IQ og vores udvælgelseskriterier fremgår det, at disse aktier er Genmab, NKT og Carlsberg. Hør mere om de forskellige aktier og mulige forklaringer på, hvorfor aktierne handles på disse niveauer.

NKT Genmab Carlsberg

Pressemeddelelse25.11.2024, 16.05

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab

Selskabsmeddelelse15.10.2024, 10.25

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Genmab

Genmab

1.377

DKK

+0,33 %

Finanskalender

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Join Inderes community

Inderes account

Aktier i Vælten - Et tilbageblik på bevægelserne i OMXC25 i 2024, og nogle forudsigelser for 2025

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Aktier i Vælten - Genmab, NKT og Carlsberg: Er de på tilbud her i Black Week?

Genmab to Present at Citi’s Global Healthcare Conference

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Announces Financial Results for the First Nine Months of 2024

Genmab to Present at Jefferies London Healthcare Conference

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Major Shareholder Announcement

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial